ConductScience.org, home

Comparison · NCT00719186-05e3000b

Arm A: Clomiphene Citrate vs Arm B: Letrozole: Live Birth

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Arm A: Clomiphene Citrate vs Arm B: Letrozole: Live Birth. Trial comparisons, record NCT00719186-05e3000b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00719186-05e3000b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1910.1550.234wilson
Risk in group 20.2750.2330.323wilson
Risk difference, group 1 minus group 2-0.0839-0.144-0.0234newcombe hybrid score
Risk ratio, group 1 over group 20.6950.5340.906log
Odds ratio, group 1 over group 20.6230.4420.878log
Number needed to treat, for one fewer participant with the outcome on Arm A: Clomiphene Citrate than on Arm B: Letrozole11.96.9642.8from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Arm A: Clomiphene Citrate
Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks~Clomiphene citrate: Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
72376OG000
Group 2Arm B: LetrozoleLetrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks~Letrozole: Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks103374OG001

Outcome

Type
PRIMARY
Title
Live Birth
Description
The primary outcome measure is the occurrence of a live birth during the study period. Safety measures will be the number and type of reported adverse events in subjects and offspring.
Time frame
as few as 5 months, up to 16 months
Population

Source ClinicalTrials.gov

Trial

Title
Pregnancy in Polycystic Ovary Syndrome II
NCT number
NCT00719186
Phases
PHASE3
Conditions
Pregnancy, Polycystic Ovary Syndrome
Interventions
Clomiphene citrate, Letrozole
Lead sponsor
Yale University
Results first posted
2014-06-09

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00719186-05e3000b